Pengyang Medical Secures Series B++ Funding from Jianchuang Healthcare Growth Fund to Accelerate Industrialization of Cardiovascular Diagnostic Platform and Multi-Center Expansion

VCBeat (WeChat ID: vcbeat) has learned, provider of smart cardiovascular diagnosis service platforms—Beijing Pengyang Fengye Medical Equipment Co., Ltd. (hereinafter referred to as "Pengyang Medical"), recently completed a B++ round of financing amounting to tens of millions of yuan, invested by the Jianchuang Medical Growth Fund (Lishui Liandu District Jianchuang Big Health Venture Investment Fund Partnership (Limited Partnership)). Leveraging this round of financing and relying on the industrial support and resource advantages of the Lishui government, Pengyang Medical will accelerate the industrial implementation and multi-center development of its cardiovascular diagnostic service platform, laying a solid foundation and providing strong guarantees for building a full-cycle cardiovascular diagnostic service ecosystem and achieving an IPO.

This latest funding round marks another vote of confidence from investors in Pengyang Medical, following the completion of its tens-of-millions-yuan Series B+ financing in 2023. It underscores the capital market’s strong interest in the cardiovascular diagnostics sector and reflects full confidence in Pengyang Medical’s team, technology, products, and market prospects.

Pengyang Medical focuses on technological innovation, as well as the research and development, manufacturing, and sales of products in the cardiovascular field. It has developed a series of intelligent monitoring and AI-based diagnostic products, represented by its globally exclusive patented product—the 18-lead ambulatory ECG analysis system. Twelve of its products have obtained NMPA certification, and three have received CE certification. The company holds six national invention patents, twelve utility model patents, and twenty-six computer software copyrights. Looking ahead, it aims to continuously build a patent pool comprising more than one hundred patents. As a high-end manufacturer with leading original technologies and strong product commercialization capabilities, Pengyang Medical is recognized as a National High-Tech Enterprise and a Beijing “Specialized, Refined, Differential, and Innovative” (SRDI) enterprise.

Pengyang Medical is the only enterprise awarded the title of “R&D Base for 18-Lead Ambulatory ECG Technology” by the Chinese Society of Electrocardiology; it is a founding member of the China County-Level Medical Community Alliance and an industry-standard enterprise for the National TCM Cardiovascular Standardized Diagnosis and Treatment Center. The “Pengyang ECG Intelligent AI Diagnostic System” won the First Prize in the 2018 National Medical Artificial Intelligence Competition, and the “18-Lead Ambulatory ECG Diagnostic System” won the First Prize in the 4th China Medical Device Innovation and Entrepreneurship Competition in 2021. In 2021, the “Expert Consensus on 18-Lead Ambulatory Electrocardiography” was published in the authoritative industry journal *Chinese Journal of Cardiovascular Research*.

Driven by the dual engines of technology and market innovation, Pengyang Medical has seized the opportunity presented by the National Health Commission’s release of the “Implementation Plan for the Healthy China Action—Prevention and Control of Cardiovascular and Cerebrovascular Diseases (2023–2030).” Targeting millions of primary healthcare institutions, tens of thousands of tiered hospitals, and hundreds of millions of cardiovascular patients, the company provides professional and convenient screening and diagnostic services for cardiovascular diseases, addressing the pain points in disease screening and diagnosis faced by both patients and primary healthcare providers. Currently, Pengyang’s Cloud ECG Smart Cardiovascular Diagnostic Service Platform has established a national-level consultation center and collaborated with provincial Grade A tertiary hospitals across China to set up regional remote ECG diagnostic sub-centers. By providing precise detection equipment to primary healthcare institutions and linking them with high-quality medical resources from higher-level hospitals, the platform enhances primary care capabilities, better advancing the goals of cardiovascular disease prevention and control under the Healthy China initiative. It also meets the needs of cardiovascular patients for accessible, timely, and precisely managed medical care close to home. With outstanding capabilities in technological and business model innovation, Pengyang Medical has achieved strong market feedback and progress through in-depth market deployment and operations in multiple regions. Looking ahead, Pengyang Medical will continue to scale its model, expand coverage across China’s healthcare institution market, and pursue ecological collaborations with new channels such as health check-ups, elderly care, and insurance, aiming to build China’s most authoritative and medically valuable cardiovascular diagnostic service platform.

Images of Practical Application Scenarios on Selected Platforms

Jianchuang Medical Growth Fund is a new-phase healthcare industry fund established in Liandu District, Lishui City. The team possesses many years of experience in fund management and industry investment research, with a focus on equity investments in the medical and health sector. Leveraging Liandu District’s resource advantages, favorable business environment, and robust policy support, the fund covers investment stages from angel rounds to pre-IPO. Its primary investment areas include innovative drugs, innovative medical devices, and in vitro diagnostics (IVD). The fund aims to establish a comprehensive, multi-regional industrial portfolio while also empowering portfolio companies to facilitate their growth.